Is L-Carnitine Safe to Take?
Sawicka et al. (2020) published a safety review in the Journal of the International Society of Sports Nutrition and concluded that L-carnitine supplementation at doses up to 2 g/day is safe for long-term use in healthy adults, with a side effect profile described as minimal (PMID: 32958033). Randomized controlled trials lasting up to 12 months have reported no serious adverse events at standard supplemental doses (500-2,000 mg/day). The most common side effects at therapeutic doses are mild and gastrointestinal in nature. The primary safety concern is not direct toxicity but rather the production of trimethylamine-N-oxide (TMAO) through gut microbial metabolism, addressed in detail below.
What Are the Common Side Effects of L-Carnitine?
The most frequently reported side effects of L-carnitine supplementation are gastrointestinal and dose-dependent. At standard doses of 500-2,000 mg/day, side effects are uncommon and mild. At doses of 3 g/day and above, the following effects become more frequent:
- Nausea and stomach upset — reported in approximately 5-10% of participants in clinical trials using higher doses, typically resolving within 1-2 weeks of continued use
- Diarrhea and abdominal cramping — more common when L-carnitine is taken on an empty stomach or at single doses above 2 g
- Fishy body odor — caused by excretion of trimethylamine (TMA), a breakdown product of carnitine metabolism by intestinal bacteria. This odor affects sweat, breath, and urine
- Heartburn — occasionally reported, particularly with base L-carnitine compared to the LCLT form
These side effects are managed by reducing the dose, splitting daily intake into smaller servings, and taking L-carnitine with meals. The fishy odor can persist as long as supplementation continues at higher doses and is the most common reason users discontinue L-carnitine.
What Is the TMAO Concern with L-Carnitine?
Koeth et al. (2013) published a study in Nature Medicine demonstrating that intestinal bacteria convert L-carnitine into trimethylamine (TMA), which the liver then oxidizes to trimethylamine-N-oxide (TMAO) (PMID: 23563705). In animal models, TMAO promoted atherosclerotic plaque development. Higher plasma TMAO levels also correlated with increased cardiovascular event risk in observational human studies. Notably, omnivores produced more TMAO from L-carnitine than vegans or vegetarians, because habitual meat consumption selects for TMA-producing gut bacteria.
Buffa et al. (2022) identified the specific microbial gene cluster (gbu) responsible for converting L-carnitine to TMA in Nature Microbiology, establishing the molecular mechanism behind the observational associations (PMID: 34949826). This finding confirmed that TMAO production from carnitine is a real metabolic pathway, not an artifact of observational study design.
A genuine paradox exists in the L-carnitine evidence base: interventional trials (meta-analyses by DiNicolantonio et al. 2013 and Shang et al. 2014) show cardiovascular benefit from L-carnitine supplementation, while observational data links the TMAO produced from that same supplementation to cardiovascular risk. The resolution may involve dose, duration, or population-specific factors. At present, the interventional evidence showing benefit in post-MI patients remains the stronger tier of evidence, but long-term TMAO monitoring in chronic L-carnitine users is warranted.
Does L-Carnitine Interact with Medications?
L-Carnitine has documented interactions with several medication categories:
- Warfarin and anticoagulants — L-Carnitine may potentiate the blood-thinning effect of warfarin, increasing INR values and bleeding risk. Individuals on anticoagulant therapy should consult their prescriber before supplementing
- Thyroid medications — L-Carnitine may inhibit thyroid hormone entry into cells, potentially reducing the effectiveness of thyroid hormone replacement therapy (levothyroxine). Patients on thyroid medication should have thyroid levels monitored if adding L-carnitine
- Anticonvulsant drugs — Valproic acid and certain other anticonvulsants can deplete carnitine levels. In these cases, L-carnitine supplementation may be therapeutically appropriate but should be supervised by the prescribing neurologist
- Acenocoumarol — Similar interaction profile to warfarin, with potential INR increases
Any individual on prescription medication should consult a healthcare provider before starting L-carnitine supplementation.
Is L-Carnitine Safe During Pregnancy?
L-Carnitine is a naturally occurring compound, and plasma carnitine levels decline during pregnancy due to increased metabolic demands and renal clearance. There is no evidence that L-carnitine supplementation at standard doses is harmful during pregnancy, but there is also limited clinical trial data specifically evaluating supplemental L-carnitine in pregnant women. Pregnant or nursing women should consult their obstetrician before supplementing.
Who Should Avoid L-Carnitine?
Several populations should exercise caution or avoid L-carnitine supplementation without medical supervision:
- Individuals with active cardiovascular disease — The TMAO concern creates ambiguity for primary prevention. Post-MI patients have demonstrated benefit, but supplementation for general cardiovascular prevention in healthy individuals lacks clear support
- People with trimethylaminuria — A genetic condition that impairs TMA metabolism, causing severe body odor. L-carnitine supplementation would worsen symptoms
- Individuals on anticoagulant therapy — Potential warfarin potentiation requires medical monitoring
- Patients with hypothyroidism on levothyroxine — L-carnitine may reduce thyroid hormone cellular uptake
- Individuals with seizure disorders — While L-carnitine can help carnitine depletion caused by anticonvulsants, dosing must be supervised
What Does Long-Term Safety Data Show?
Clinical trials of L-carnitine supplementation lasting up to 12 months have not identified serious adverse events at doses of 2 g/day or below (PMID: 32958033). The cardiovascular meta-analyses included trials with supplementation periods ranging from weeks to over a year, and the net clinical outcome was benefit, not harm (PMID: 23597877). L-Carnitine does not appear to suppress endogenous carnitine synthesis, and discontinuation produces a gradual return to baseline tissue levels without withdrawal effects.
The unresolved long-term question is whether chronic TMAO increases from years of daily L-carnitine supplementation carries cumulative cardiovascular risk that outweighs the documented benefits. Multi-year prospective studies specifically tracking TMAO levels and cardiovascular outcomes in L-carnitine supplement users have not yet been published. Until such data exist, maintaining doses at or below 2 g/day represents a reasonable risk-management approach.
This content is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any supplement.